Estudio de MK-3655 en personas con esteatohepatitis no alcohólica precirrótica
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis